Across its top 16 institutional holders, ESLA's holder base skews toward low-concentration, low-turnover investors on average (avg. concentration score 6/100, avg. turnover score 29/100).

Quarterly Activity

Recent Activity

+$5.2M

Total Buy Value

$533.4K

Total Sell Value

New buy7

Trim2

Add3

Sold out6

Net Buyers

Net Sellers

Smart Money Convergence

ESLA does not currently have enough recent insider (Form 4) trading activity to compute a convergence signal against its 13F institutional flows.

13F data as of 2026-03-31 quarterly filings. Note: many large institutions file close to the 45-day post-quarter deadline, so early-quarter flow figures can shift substantially as more filings arrive.

Insider Trading (Form 4)

Form 144 Pre-Sale Notices

No Form 144 planned sale filings in the last 90 days

Beneficial Ownership (13D/13G)

No Schedule 13D/13G filings for this ticker

Material Events (8-K)

Filings (14d)

Data as of 2026-06-30

2026-06-30

Estrella Immunopharma held its annual meeting on June 29, 2026, with shareholders voting to ratify the appointment of Macias Gini & O'Connell LLP as its independent accounting firm for the 2026 fiscal year. The vote passed overwhelmingly with over 30.35 million shares in favor and only 400 against.

View Full Filing (SEC EDGAR)

View all Form 8-K filings

CUSIP

297584104

FAQ

Who are the top institutional investors holding ESTRELLA IMMUNOPHARMA INC (ESLA)?

Major stakeholders currently include Armistice Capital, LLC ($4.3M), Vanguard Capital Management LLC ($405.4K), Wells Fargo & Company/mn ($280.3K). Based on the latest 13F filings, there are a total of 16 tracked investment funds and institutions maintaining positions in ESLA.

What is the overall institutional sentiment toward ESLA recently?

Institutional sentiment appears Bullish (Net Buying). During the most recent reporting quarter, the stock experienced a net inflow of $3.9M, driven by 10 managers accumulating shares while 8 reduced their exposure.

Which institutions have been selling or reducing their ESLA positions?

In the latest period, 2 funds trimmed their holdings, and 6 managers completely exited their positions. The aggregate reported sell value was $533.4K.

Are there any notable investors adding ESLA to their portfolios?

Yes, buying activity remains notable. 7 institutions opened new positions in {ticker}, and 3 existing holders added to their shares. The total reported buy value for the quarter amounted to $5.2M.